Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao(Broad Institute), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Bastian Schilling(Goethe University Frankfurt), Adam Tracy(Broad Institute), Kwok‐Kin Wong(NYU Langone Health), Paz Polak(Broad Institute), Dennis O. Adeegbe(Moffitt Cancer Center), Dirk Schadendorf(National Center for Tumor Diseases), Glenn J. Hanna(Dana-Farber Cancer Institute), Jeffrey A. Engelman(Cancer Research Center), Stephanie A. Wankowicz(Vanderbilt University), Sabina Signoretti(Brigham and Women's Hospital), Pasi A. Jänne(Harvard University), Toni K. Choueiri(Harvard University), Claire A. Margolis(Broad Institute), Scott J. Rodig(Brigham and Women's Hospital), David A. Barbie(Dana-Farber Cancer Institute), Michael P. Manos(Harvard University), Joaquim Bellmunt(Dana-Farber Cancer Institute), Amaro Taylor‐Weiner(Critical Path Institute), Robert I. Haddad(Georgetown University), Daniel Keliher(Broad Institute), F. Stephen Hodi(Harvard University), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Natalie I. Vokes(The University of Texas MD Anderson Cancer Center), Lynette M. Sholl(Brigham and Women's Hospital), Rizwan Haq(Ontario Institute for Cancer Research), David Liu(University of Louisville), Gad Getz(Broad Institute), Nicole G. Chau(University of British Columbia), Peter S. Hammerman(Broad Institute)
Cited by 701
Related Papers
Integrative genomics viewer
|Nature Biotechnology|2011|16.5k
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k